TLR4-HMGB1 signaling pathway affects the inflammatory reaction of autoimmune myositis by regulating MHC-I

International Immunopharmacology

Volumn 41, Issue , 2016, Pages 74-81

  Wan, Zemin ^a   Zhang, Xiujuan ^a   Peng, Anping ^a   He, Min ^a   Lei, Zhenhua ^a   Wang, Yunxiu ^a  

^a GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

Author keywords

Autoimmune myositis; MHC I; Proinflammatory cytokines; TLR4 HMGB1 signaling pathway

Indexed keywords

GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; HLA ANTIGEN CLASS 1; HMGB1 PROTEIN, MOUSE; INTERLEUKIN-6, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MUSCLE EXERCISE; MYOSITIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; GENETICS; METABOLISM; MONONUCLEAR CELL; SKELETAL MUSCLE;

ANIMALS; AUTOIMMUNE DISEASES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HMGB1 PROTEIN; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MYOSITIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84994268347     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.10.009     Document Type: Article

References (52)

1. [1] Allenbach, Y., Solly, S., Gregoire, S., Dubourg, O., Salomon, B., Butler-Browne, G., et al. Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. Am. J. Pathol. 174 (2009), 989–998.
2. [2] Hoogendijk, J.E., Amato, A.A., Lecky, B.R., Choy, E.H., Lundberg, I.E., Rose, M.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscular disorders: NMD 14 (2004), 337–345.
3. [3] Troyanov, Y., Targoff, I.N., Tremblay, J.L., Goulet, J.R., Raymond, Y., Senecal, J.L., Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84 (2005), 231–249.
4. [4] Meyer, A., Meyer, N., Schaeffer, M., Gottenberg, J.E., Geny, B., Sibilia, J., Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology 54 (2015), 50–63.
5. [5] Hamann, P.D., Cooper, R.G., McHugh, N.J., Chinoy, H., Statin-induced necrotizing myositis - a discrete autoimmune entity within the “statin-induced myopathy spectrum”. Autoimmun. Rev. 12 (2013), 1177–1181.
6. [6] Luo, Y.B., Mastaglia, F.L., Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim. Biophys. Acta 2015 (1852), 622–632.
7. [7] Lahouti, A.H., Christopher-Stine, L., Polymyositis and dermatomyositis: novel insights into the pathogenesis and potential therapeutic targets. Discov. Med. 19 (2015), 463–470.
8. [8] Ulfgren, A.K., Grundtman, C., Borg, K., Alexanderson, H., Andersson, U., Harris, H.E., et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum. 50 (2004), 1586–1594.
9. [9] Zong, M., Bruton, J.D., Grundtman, C., Yang, H., Li, J.H., Alexanderson, H., et al. TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann. Rheum. Dis. 72 (2013), 1390–1399.
10. [10] Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., et al. HMGB1 in health and disease. Mol. Asp. Med. 40 (2014), 1–116.
11. [11] Wang, X., Xiang, L., Li, H., Chen, P., Feng, Y., Zhang, J., et al. The role of HMGB1 signaling pathway in the development and progression of hepatocellular carcinoma: a review. Int. J. Mol. Sci. 16 (2015), 22527–22540.
12. [12] Li, J., Kokkola, R., Tabibzadeh, S., Yang, R., Ochani, M., Qiang, X., et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med. 9 (2003), 37–45.
13. [13] Kim, S., Kim, S.Y., Pribis, J.P., Lotze, M., Mollen, K.P., Shapiro, R., et al. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol. Med. 19 (2013), 88–98.
14. [14] Huang, W., Tang, Y., Li, L., HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 51 (2010), 119–126.
15. [15] Lotze, M.T., Tracey, K.J., High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5 (2005), 331–342.
16. [16] Chen, Y., Sun, W., Gao, R., Su, Y., Umehara, H., Dong, L., et al. The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis. Rheumatology 52 (2013), 1739–1747.
17. [17] Gardella, S., Andrei, C., Ferrera, D., Lotti, L.V., Torrisi, M.R., Bianchi, M.E., et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3 (2002), 995–1001.
18. [18] Porto, A., Palumbo, R., Pieroni, M., Aprigliano, G., Chiesa, R., Sanvito, F., et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 20 (2006), 2565–2566.
19. [19] Pisetsky, D.S., Erlandsson-Harris, H., Andersson, U., High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res. Ther., 10, 2008, 209.
20. [20] Abdulahad, D.A., Westra, J., Bijzet, J., Limburg, P.C., Kallenberg, C.G., Bijl, M., High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis research & therapy., 13, 2011, R71.
21. [21] Grundtman, C., Bruton, J., Yamada, T., Ostberg, T., Pisetsky, D.S., Harris, H.E., et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24 (2010), 570–578.
22. [22] Andersson, U., Wang, H., Palmblad, K., Aveberger, A.C., Bloom, O., Erlandsson-Harris, H., et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192 (2000), 565–570.
23. [23] Scaffidi, P., Misteli, T., Bianchi, M.E., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002), 191–195.
24. [24] Yang, H., Hreggvidsdottir, H.S., Palmblad, K., Wang, H., Ochani, M., Li, J., et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 11942–11947.
25. [25] Takeuchi, O., Akira, S., Pattern recognition receptors and inflammation. Cell 140 (2010), 805–820.
26. [26] Yamamoto, M., Takeda, K., Current views of toll-like receptor signaling pathways. Gastroenterol. Res. Pract., 2010, 2010, 240365.
27. [27] Aderem, A., Ulevitch, R.J., Toll-like receptors in the induction of the innate immune response. Nature 406 (2000), 782–787.
28. [28] Re, F., Strominger, J.L., Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 276 (2001), 37692–37699.
29. [29] Tournadre, A., Lenief, V., Miossec, P., Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum. 62 (2010), 2144–2151.
30. [30] Frost, R.A., Nystrom, G.J., Lang, C.H., Multiple Toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290 (2006), R773–R784.
31. [31] Confalonieri, P., Oliva, L., Andreetta, F., Lorenzoni, R., Dassi, P., Mariani, E., et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J. Neuroimmunol. 142 (2003), 130–136.
32. [32] Salomonsson, S., Grundtman, C., Zhang, S.J., Lanner, J.T., Li, C., Katz, A., et al. Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle. Muscle Nerve 39 (2009), 674–682.
33. [33] Katsumata, Y., Harigai, M., Sugiura, T., Kawamoto, M., Kawaguchi, Y., Matsumoto, Y., et al. Attenuation of experimental autoimmune myositis by blocking ICOS-ICOS ligand interaction. J. Immunol. 179 (2007), 3772–3779.
34. [34] Contet, C., Rawlins, J.N., Deacon, R.M., A comparison of 129S2/SvHsd and C57BL/6JOlaHsd mice on a test battery assessing sensorimotor, affective and cognitive behaviours: implications for the study of genetically modified mice. Behav. Brain Res. 124 (2001), 33–46.
35. [35] Dey, B.K., Gagan, J., Yan, Z., Dutta, A., miR-26a is required for skeletal muscle differentiation and regeneration in mice. Genes Dev. 26 (2012), 2180–2191.
36. [36] Ieronimakis, N., Pantoja, M., Hays, A.L., Dosey, T.L., Qi, J., Fischer, K.A., et al. Increased sphingosine-1-phosphate improves muscle regeneration in acutely injured mdx mice. Skelet. Muscle, 3, 2013, 20.
37. [37] Kruger, N.J., The Bradford method for protein quantitation. Methods Mol. Biol. 32 (1994), 9–15.
38. [38] Rodriguez Cruz, P.M., Luo, Y.B., Miller, J., Junckerstorff, R.C., Mastaglia, F.L., Fabian, V., An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscular disorders: NMD 24 (2014), 1025–1035.
39. [39] Cseri, K., Vincze, J., Cseri, J., Fodor, J., Csernatony, Z., Csernoch, L., et al. HMGB1 expression and muscle regeneration in idiopathic inflammatory myopathies and degenerative joint diseases. J. Muscle Res. Cell Motil. 36 (2015), 255–262.
40. [40] Englund, P., Nennesmo, I., Klareskog, L., Lundberg, I.E., Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum. 46 (2002), 1044–1055.
41. [41] Campana, L., Bosurgi, L., Rovere-Querini, P., HMGB1: a two-headed signal regulating tumor progression and immunity. Curr. Opin. Immunol. 20 (2008), 518–523.
42. [42] Levy, R.M., Mollen, K.P., Prince, J.M., Kaczorowski, D.J., Vallabhaneni, R., Liu, S., et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 (2007), R1538–R1544.
43. [43] Muth, I.E., Zschuntzsch, J., Kleinschnitz, K., Wrede, A., Gerhardt, E., Balcarek, P., et al. HMGB1 and RAGE in skeletal muscle inflammation: implications for protein accumulation in inclusion body myositis. Exp. Neurol. 271 (2015), 189–197.
44. [44] Xu, Y., Jagannath, C., Liu, X.D., Sharafkhaneh, A., Kolodziejska, K.E., Eissa, N.T., Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27 (2007), 135–144.
45. [45] Delgado, M.A., Deretic, V., Toll-like receptors in control of immunological autophagy. Cell Death Differ. 16 (2009), 976–983.
46. [46] Kim, G.T., Cho, M.L., Park, Y.E., Yoo, W.H., Kim, J.H., Oh, H.J., et al. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin. Rheumatol. 29 (2010), 273–279.
47. [47] Doyle, A., Zhang, G., Abdel Fattah, E.A., Eissa, N.T., Li, Y.P., Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 25 (2011), 99–110.
48. [48] Grundtman, C., Salomonsson, S., Dorph, C., Bruton, J., Andersson, U., Lundberg, I.E., Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum. 56 (2007), 674–687.
49. [49] Nyberg, P., Wikman, A.L., Nennesmo, I., Lundberg, I., Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J. Rheumatol. 27 (2000), 940–948.
50. [50] Carrol, E.D., Thomson, A.P., Mobbs, K.J., Fraser, W.D., Sills, J.A., Hart, C.A., Myositis in children with meningococcal disease: a role for tumour necrosis factor-alpha and interleukin-8?. The Journal of Infection 44 (2002), 17–21.
51. [51] Efthimiou, P., Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin. Arthritis Rheum. 36 (2006), 168–172.
52. [52] De Rossi, M., Bernasconi, P., Baggi, F., de Waal, M.R., Mantegazza, R., Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int. Immunol. 12 (2000), 1329–1335.